Fluticasone furoate; vilanterol trifenatate - Generic Drug Details

What are the generic sources for fluticasone furoate; vilanterol trifenatate and what is the scope of patent protection?

Fluticasone furoate; vilanterol trifenatate is the generic ingredient in one branded drug marketed by Glaxo Grp Ltd and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone furoate; vilanterol trifenatate has one hundred and eighty-eight patent family members in thirty-three countries.

Two suppliers are listed for this compound.

Summary for fluticasone furoate; vilanterol trifenatate

International Patents:	188
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fluticasone furoate; vilanterol trifenatate
DailyMed Link:	fluticasone furoate; vilanterol trifenatate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for fluticasone furoate; vilanterol trifenatate

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for fluticasone furoate; vilanterol trifenatate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	PHASE4
Q2 Solutions	Phase 3
SRL Mediserch.Inc	Phase 3

See all fluticasone furoate; vilanterol trifenatate clinical trials

Pharmacology for fluticasone furoate; vilanterol trifenatate

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for fluticasone furoate; vilanterol trifenatate

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

Paragraph IV (Patent) Challenges for FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BREO ELLIPTA	Powder for Inhalation	fluticasone furoate; vilanterol trifenatate	100 mcg/25 mcg	204275	1	2025-06-16

US Patents and Regulatory Information for fluticasone furoate; vilanterol trifenatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes					Y

Expired US Patents for fluticasone furoate; vilanterol trifenatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015

International Patents for fluticasone furoate; vilanterol trifenatate

Country	Patent Number	Title	Estimated Expiration
South Korea	20040078139
Slovenia	2042168
European Patent Office	1534367
Brazil	PI0212455	composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
Cyprus	1121205
South Korea	20080031458	MEDICAMENT DISPENSER

Supplementary Protection Certificates for fluticasone furoate; vilanterol trifenatate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1425001	CR 2014 00021	Denmark		PRODUCT NAME: VILANTEROL ELLER ET SALT ELLER SOLVAT DERAF, HERUNDER VILANTEROL TRIFENATAT; REG. NO/DATE: EU/1/13/886/001-006 20131114
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
1425001	14C0028	France		PRODUCT NAME: VILANTEROL OU UN SEL OU UN SOLVATE DE CELUI-CI,EN PARTICULIER LE TRIFENATATE DE VILANTEROL.; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111

Market Dynamics and Financial Trajectory for Fluticasone Furoate; Vilanterol Trifenatate

Last updated: September 22, 2025

Introduction

The combination of Fluticasone Furoate and Vilanterol Trifenatate represents a novel therapeutic approach within the respiratory disease landscape, primarily targeting asthma and Chronic Obstructive Pulmonary Disease (COPD). As a long-acting inhaled corticosteroid and beta-agonist combo, it offers potential improvements over existing treatments. This analysis evaluates the current market dynamics and forecasts the financial trajectory of this pharmaceutical duo, accounting for regulatory developments, competitive landscape, pipeline activity, and macroeconomic factors.

Market Overview

Therapeutic Context

Respiratory diseases like asthma and COPD impose significant global health burdens, with increasing prevalence fueled by aging populations and environmental factors. The Global Initiative for Asthma (GINA) estimates over 339 million people affected worldwide, with similar trends observed for COPD, making inhaled therapies imperative for disease management.

Product Profile and Indication

Fluticasone Furoate; Vilanterol Trifenatate is marketed or in development as a once-daily inhaler, expected to improve patient adherence and clinical outcomes. It targets moderate to severe asthma and COPD, aligning with the escalating demand for effective maintenance therapies.

---

Market Dynamics

Regulatory Environment

The regulatory trajectory significantly influences market potential. In recent years, agencies like the FDA and EMA have emphasized rigorous clinical efficacy and safety evaluations for combination inhalers. Notably, the U.S. FDA approved similar combinations—such as Fluticasone Furoate; Vilanterol—positioning the current drug within a favorable regulatory landscape. Regulatory approvals expedite market entry but require compliance with stringent guidelines, impacting development timelines and costs.

Competitive Landscape

The market for combination inhalers is saturated with established therapies:

• Fluticasone Propionate and Vilanterol combinations (e.g., Breo Ellipta) dominate due to extensive clinical evidence.
• Innovative entrants, including GSK's Kaftrio and Trelegy Ellipta, continue to challenge depending on efficacy, safety profiles, and pricing.
• Fluticasone Furoate; Vilanterol Trifenatate faces competition from these agents, but its differentiated profile—potentially improved tolerability or pharmacokinetics—may support niche colonization.

Intellectual Property and Patent Status

Patent protections dictate market exclusivity. Patents covering Vilaterol and Fluticasone Furoate extend through 2030-2035 in major markets, providing a window for revenue growth. Patent expirations could open the market to generic competition, compressing prices.

Pricing and Reimbursement

Pricing strategies hinge on clinical value, manufacturing costs, and negotiations with payers. Premium pricing is justified by superior efficacy, convenience, or safety. Reimbursement policies vary globally; countries with robust healthcare funding models offer better revenue prospects. In the U.S., reimbursement codes for inhalers facilitate commercial uptake.

Market Penetration and Adoption

Physician and patient acceptance depend on demonstration of clear clinical benefits, minimal side effects, and ease of use. Educational initiatives and clinical guidelines influence prescribing behaviors, directly affecting sales volume.

---

Financial Trajectory Forecast

Revenue Projections

Projected revenues for Fluticasone Furoate; Vilanterol Trifenatate hinge on multiple factors:

• Market penetration rates: Initial adoption in the U.S. and Europe expected to reach 10-15% of the target population within 3-5 years post-launch.
• Pricing strategies: Premium pricing could generate $2000-$3000 per inhaler annually, translating into significant revenues given projected patient numbers.
• Global expansion: Entry into emerging markets (e.g., Asia-Pacific, Latin America) offers sizeable growth opportunities, albeit with pricing downtrends and reimbursement uncertainties.

Cost Structure and Investment

Development costs, including clinical trials and regulatory fees, are substantial—estimated at several hundred million dollars. Marketing, distribution, and manufacturing further influence profit margins. In early stages, investments are front-loaded; profitability may materialize over 5-7 years.

Profitability Outlook

With patent protection and a favorable competitive environment, the drug could achieve gross margins of 60-70%. Break-even is feasible within 3-4 years post-launch, assuming successful market uptake and controlled costs.

Risk Factors and Mitigation

• Regulatory delays or rejection could postpone revenues.
• Emergence of generic competitors post-patent expiry would pressure prices.
• Market acceptance depends on clinical trial outcomes and real-world effectiveness.
• Pricing pressures from payers, especially in cost-conscious markets, may constrain revenue.

---

Emerging Trends Influencing Future Outlook

Personalized Medicine and Digital Integration

Advances in pharmacogenomics and digital inhaler technologies promise improved treatment precision and adherence, potentially transforming market dynamics in favor of innovative combination therapies like Fluticasone Furoate; Vilanterol Trifenatate.

Pipeline Development

Ongoing clinical trials exploring novel formulations and combinations could enhance drug profile and expand indications, bolstering long-term revenues.

Regulatory and Policy Shifts

Global shifts toward value-based care and cost containment may necessitate demonstrating superior clinical outcomes, influencing reimbursement and pricing strategies.

---

Conclusion

The market for Fluticasone Furoate; Vilanterol Trifenatate operates within a complex web of regulatory, competitive, and macroeconomic factors. While initial commercial prospects appear promising, success will depend on clinical efficacy, strategic positioning, and navigating patent landscapes. Anticipated growth, especially entering emerging markets, suggests a positive financial trajectory over the next decade, contingent upon effective execution and adaptation to evolving healthcare policies.

---

Key Takeaways

• The respiratory therapeutic market remains high-growth, driven by rising prevalence and unmet needs.
• Patent protections and regulatory approvals are critical for early revenue gains.
• Competitive landscape is intense; differentiation through efficacy and safety is essential.
• Market penetration depends on physician acceptance and reimbursement frameworks.
• Long-term profitability hinges on pipeline success, patent management, and strategic expansion.

---

Frequently Asked Questions

1. What is the primary advantage of Fluticasone Furoate; Vilanterol Trifenatate over existing inhalers?

It offers once-daily dosing with potentially improved adherence, combined with established efficacy in reducing exacerbations in asthma and COPD. Its novel formulation may also present better tolerability profiles.

2. How does patent expiration impact the drug’s financial outlook?

Patents typically provide exclusivity for 10-15 years. Once expired, patent protections lapse, opening the market to generic competition, which can significantly reduce prices and profit margins.

3. What are the main regulatory challenges for this drug?

Ensuring consistent clinical efficacy, managing safety concerns such as cardiovascular risks associated with long-acting beta-agonists, and meeting distinct regional approval requirements are key hurdles.

4. Which markets present the most growth opportunities?

The U.S. and Europe offer mature markets with high prevalence and reimbursement systems. Emerging markets like China, India, and Southeast Asia offer growth potential due to expanding healthcare infrastructure and rising disease burden.

5. How does the competitive landscape influence the drug’s market success?

Existing long-acting inhalers with proven track records set high entry barriers. Differentiation through improved outcomes, dosing convenience, or cost-effectiveness is necessary to capture market share.

---

References

[1] Global Initiative for Asthma. (2022). Global Strategy for Asthma Management and Prevention.
[2] European Respiratory Society. (2022). COPD Management Guidelines.
[3] FDA. (2021). Approved Drugs Database.
[4] MarketWatch. (2022). Respiratory Disease Therapeutics Market Analysis.
[5] PatentScope. (2023). Patent Landscape for Inhaled Corticosteroids and Beta-Agonists.